

# Mitchell S Von Itzstein

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7434573/mitchell-s-von-itzstein-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

89  
citations

5  
h-index

9  
g-index

24  
ext. papers

190  
ext. citations

5  
avg, IF

3.04  
L-index

#	Paper	IF	Citations
20	Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.. <i>Cancer Immunology, Immunotherapy</i> , <b>2022</b> , 1	7.4	2
19	Association between immune-related adverse event timing and treatment outcomes.. <i>Oncolimmunology</i> , <b>2022</b> , 11, 2017162	7.2	2
18	Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 3, 100291	1.4	0
17	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors <b>2021</b> , 9,		1
16	Assessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e999-e1011	2.3	
15	Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers. <i>Cancer Research</i> , <b>2021</b> , 81, 3441-3443	10.1	
14	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 779-793	5.5	32
13	Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , <b>2020</b> , 25, e1242-e1245	5.7	5
12	Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud&#x2013;Like Phenomenon. <i>Oncologist</i> , <b>2020</b> , 25, e753-e757	5.7	8
11	Closing the gap: Contribution of surgical best practices to outcome differences between high- and low-volume centers for lung cancer resection. <i>Cancer Medicine</i> , <b>2020</b> , 9, 4137-4147	4.8	3
10	Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. <i>Cancer</i> , <b>2020</b> , 126, 1605-1613	6.4	3
9	Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231258	3.7	2
8	Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15126-e15126	2.2	
7	Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3043-3043	2.2	
6	Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , <b>2020</b> , 15, 579-588	5	3
5	Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?. <i>EBioMedicine</i> , <b>2020</b> , 60, 103006	8.8	
4	Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. <i>Lung</i> , <b>2019</b> , 197, 593-599	2.9	5

3	Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer. <i>Cancer</i> , <b>2019</b> , 125, 4252-4259	6.4	6
2	Strategies to maximize influenza vaccine impact in older adults. <i>Vaccine</i> , <b>2018</b> , 36, 5940-5948	4.1	11
1	Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base osteomyelitis. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	5